Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04817228 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers
A Phase 2 study, sponsored by MediWound.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04817228 is a Phase 2 study that has completed, run by MediWound. The registered enrollment target is 12 participants.
The verdict
NCT04817228, a Phase 2 study, has completed, sponsored by MediWound.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will be a multicenter, prospective, open label, one-arm study intended to assess the clinical performance and safety of EX-02 in debridement of lower leg ulcers: Venous Leg Ulcers (VLU) and Diabetic Foot Ulcer (DFU). In addition, the pharmacology effect of EX-02 will be assessed. Lower leg ulcer size between 2 cm2 and 80 cm2 (surface area).
Interventions
- DRUG EscharEx (EX-02 formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04817228
The ClinicalTrials.gov registry entry for NCT04817228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediWound, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EscharEx (EX-02 formulation) is the first listed.
NCT04817228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04817228 about?
NCT04817228 is a clinical study titled "A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers". This study will be a multicenter, prospective, open label, one-arm study intended to assess the clinical performance and safety of EX-02 in debridement of lower leg ulcers: Venous Leg Ulcers (VLU) and Diabetic Foot Ulcer (DFU). In addition, the pharmacology effect of EX-02 will be assessed. Lower l...
What is the current status of trial NCT04817228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-04-21. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT04817228?
The interventions under investigation include: EscharEx (EX-02 formulation) (DRUG).
Who is sponsoring clinical trial NCT04817228?
This trial is sponsored by MediWound, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.